

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: M. Rigdon Lentz

Serial No: 09/709,045 Art Unit: 1647

Filed: November 10, 2000 Examiner: L. Spector

METHODS AND SYSTEM TO REMOVE CYTOKINE INHIBITOR IN PATIENTS

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**TERMINAL DISCLAIMER TO OBViate A DOUBLE
PATENTING REJECTION OVER TWO ISSUED PATENTS
AND A PENDING SECOND APPLICATION**

Sir:

Petitioner, Biopheresis Technologies, LLC, is the owner of the entire interest in the above-identified application; U.S. Patent No. 6,620,382, issued on September 16, 2003; U.S. Patent No. 6,231,536, issued on May 15, 2001; and U.S.S.N. 09/699,003, as evidenced by the accompanying Statements Under 37 C.F.R. § 3.73(b). Petitioner hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. §§ 154-156 and 173 as shortened by any terminal disclaimer filed prior to the grant of U.S. Patent No. 6,620,382, U.S. Patent No. 6,231,536, and U.S.S.N. 09/699,003. Petitioner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and U.S. Patent No. 6,620,382, U.S. Patent No. 6,231,536, and U.S.S.N. 09/699,003 are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

45051253v1

1

LEN 102
077829/00005


U.S.S.N. 09/709,045

Filed: November 10, 2000

**TERMINAL DISCLAIMER TO OBLVIAE A
DOUBLE PATENTING REJECTION OVER TWO ISSUED U.S. PATENTS
AND A PENDING SECOND APPLICATION**

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

BIOFHERESIS TECHNOLOGIES, LLC

By: Name: Patricia L. Pabst, Reg. No. 31,284Title: Attorney for ApplicantsDate: October 6, 2004

43051233v1

3

LBN 102
077829/00006